- Fluidigm Corp FLDM stock is trading higher in the premarket on a report that the Company is considering a sale.
- According to a Bloomberg report, the medical technology firm is working with an adviser to see interest from possible buyers.
- The Company may garner interest from other healthcare providers and private equity firms.
- Fluidigm’s laboratory equipment helps researchers analyze cells and genomes to target conditions like cancer and immune dysfunction.
- It released a COVID-19 saliva test that received emergency use authorization last August from the FDA.
- Price Action: FLDM shares are up 7.87% at $6.85 during the premarket session on the last check Wednesday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
